Accelerating

Ophthalmic

Innovation

Strategic advisory, innovation sourcing, and operational support for ophthalmic companies, investors, and industry partners; spun out of a decade of specialized venture investing.

Service Platform

Delivering comprehensive ophthalmic expertise across the full innovation lifecycle from early-stage strategy through commercialization and business development.

Market Intelligence

//

Landscape Mapping

//

Targeted Due Dilligence

//

Comparative Analysis

//

Technology Scouting

//

Opportunity Identification

//

Marketability Assessment

//

Portfolio Restructuring

//

Valuation Analysis

//

Corporate Development

//

Strategic Partnerships

//

Deal Negotiation

//

Transaction Support

//

Clinical & Regulatory Strategy

//

Operational Buildouts

//

Critical Hire Sourcing

//

Stand-in Executive Coverage

//

Market Intelligence // Landscape Mapping // Targeted Due Dilligence // Comparative Analysis // Technology Scouting // Opportunity Identification // Marketability Assessment // Portfolio Restructuring // Valuation Analysis // Corporate Development // Strategic Partnerships // Deal Negotiation // Transaction Support // Clinical & Regulatory Strategy // Operational Buildouts // Critical Hire Sourcing // Stand-in Executive Coverage //

Proven Across the Innovation Lifecycle

Companies Built

15 ophthalmic companies funded since 2014, with hands-on involvement from pre-formation through commercialization. Engagements have included a $9M SPV, Series A co-leads, board seats from inception, and clinical mapping for a robotic cataract surgery milestone.

15 companies funded · 1,000+ technologies evaluated

Capital Mobilized

$27M deployed across the portfolio, informed by deep clinical, technical, and market diligence. ExSight-backed companies have continued to attract institutional capital well beyond initial investment — including relationships built with Lilly, RA Capital, JJDC, Novartis Venture Fund, Bios Partners, and Boehringer Ingelheim.

$27M deployed · $750M+ in follow-on capital raised

Outcomes Delivered

Four successful exits and two business development deals demonstrate value creation across the innovation lifecycle. Engagements have culminated in a $1B+ Re-Vana partnership workstream and exits including Bausch + Lomb's acquisition of Elios Vision and Novartis's acquisition of DTx Pharma.

$1B+ partnership workstream